Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade
- PMID: 9292
- DOI: 10.1007/BF00609464
Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. I. Relationship between plasma concentration and adrenergic beta-receptor blockade
Abstract
Mean steady-state plasma concentrations of alprenolol were studied in relationship to the degree of beta-blockade, in sixteen patients receiving 600 mg daily in divided doses. Steady-state alprenolol concentrations were determined from the area under the plasma concentration-time curve during one eight-hour dosage interval after treatment for six weeks. Beta-blockade during alprenolol treatment was assessed from the chronotropic response to intravenous isoprenaline compared to the response after six weeks of placebo therapy. Although there was interindividual variability in the mean steady-state alprenolol concentration (range 11 - 141 ng/ml), and in the degree of beta-blockade (7-fold), the correlation between the two variables was highly significant (r = 0.80, p less than 0.001). The prescribed dose of alprenolol (mg/kg) was not significantly correlated with the plasma level of alprenolol or the beta-blockade. The chronotropic effects of isoprenaline during placebo and alprenolol were significantly interrelated (r = 0.79, p less than 0.001).
Similar articles
-
Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.Eur J Clin Pharmacol. 1976 Jun 15;10(2):89-95. doi: 10.1007/BF00609465. Eur J Clin Pharmacol. 1976. PMID: 964292
-
Effect of alprenolol and hydralazine on plasma renin concentration in patients with arterial hypertension.Acta Med Scand. 1975 Nov;198(5):379-83. doi: 10.1111/j.0954-6820.1975.tb19560.x. Acta Med Scand. 1975. PMID: 1199814
-
Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol.Clin Pharmacol Ther. 1979 Apr;25(4):416-22. doi: 10.1002/cpt1979254416. Clin Pharmacol Ther. 1979. PMID: 34497 No abstract available.
-
Beta-adrenergic blockade in hypertension.Am Heart J. 1977 Mar;93(3):394-402. doi: 10.1016/s0002-8703(77)80260-3. Am Heart J. 1977. PMID: 14497 Review. No abstract available.
-
[Beta adrenergic drugs in arterial hypertension].Union Med Can. 1972 Jul;101(7):1336-41. Union Med Can. 1972. PMID: 4402882 Review. French. No abstract available.
Cited by
-
Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.Eur J Clin Pharmacol. 1976 Jun 15;10(2):89-95. doi: 10.1007/BF00609465. Eur J Clin Pharmacol. 1976. PMID: 964292
-
A standard approach to compiling clinical pharmacokinetic data.J Pharmacokinet Biopharm. 1981 Feb;9(1):59-127. doi: 10.1007/BF01059343. J Pharmacokinet Biopharm. 1981. PMID: 7014827
-
Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.Br J Clin Pharmacol. 1980 Aug;10(2):121-6. doi: 10.1111/j.1365-2125.1980.tb01728.x. Br J Clin Pharmacol. 1980. PMID: 6252915 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources